51 results on '"Luft, Thomas"'
Search Results
2. Computing solution spaces for gear box design.
- Author
-
Ziegler, Klara, Demir, Kutay, Luft, Thomas, Mucks, Thomas, Fürst, Marius, Otto, Michael, Stahl, Karsten, Vogel-Heuser, Birgit, and Zimmermann, Markus
- Subjects
DESIGN education ,NEW product development ,ENGINEERING design ,GEARING machinery ,MATHEMATICAL optimization - Abstract
The design of gear boxes is a complex challenge characterized by conflicting requirements and seemingly circular dependencies. Existing tools support engineers but focus on a single predefined design, often leading to costly iterative processes and non-optimal solutions. Solution Space Engineering (SSE) alleviates this by generating multiple designs represented by solution spaces. For this, a particular model structure is needed, and thus restructuring existing models, e.g., from industry standards. The application of solution spaces to a two-stage gear box is presented. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Prehabilitative high-intensity interval training and resistance exercise in patients prior allogeneic stem cell transplantation.
- Author
-
Kuehl, Rea, Feyer, Jule, Limbach, Matthias, Pahl, Antonia, Stoelzel, Friederike, Beck, Heidrun, Wegner, Annika, Rosenberger, Friederike, Dreger, Peter, Luft, Thomas, and Wiskemann, Joachim
- Subjects
STEM cell transplantation ,RESISTANCE training ,INTERVAL training ,HIGH-intensity interval training ,EXERCISE therapy ,PHYSICAL mobility ,PATIENT reported outcome measures - Abstract
Physical capacity prior allogeneic stem cell transplantation (allo-HCT) has been shown as a relevant prognostic factor for survival after transplant. Therefore, we evaluated feasibility and preliminary efficacy of a high-intensity interval training (HIIT) and moderate to high-intensity resistance exercise (RE) to increase physical capacity in patient's prior allo-HCT. In this multicentre single arm pilot study, a supervised exercise program was performed twice weekly for 4–12 weeks prior allo-HCT, depending on the individual time remaining. Outcomes were feasibility (recruitment, adherence, safety), physical capacity (cardiorespiratory fitness [VO2peak], muscle strength) and patient reported outcomes (physical functioning, fatigue). Thirty patients were intended, 16 could be included, and 14 completed post intervention assessment (75% male, 55 ± 11 years). The study was stopped early due to a low recruitment rate. Nine patients (64%) reached the initial minimum planned number of eight exercise sessions. Individual adherence was high with 92% for HIIT and 85% for RE. 87% of all performed exercise sessions were completed without complaints and VO2peak increased significantly from 20.4 to 23.4 ml/kg/min. The low recruitment rate suggests that initiation of the intervention concept immediately before allo-HCT is feasible only in a small number of patients. In particular, the timeframe directly prior allo-HCT seems too short for exercise interventions, although the exercise program was designed to improve outcomes in a very short time frame. HIIT and RE were feasible, effective and well accepted by the included patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Prehabilitative high-intensity interval training and resistance exercise in patients prior allogeneic stem cell transplantation.
- Author
-
Kuehl, Rea, Feyer, Jule, Limbach, Matthias, Pahl, Antonia, Stoelzel, Friederike, Beck, Heidrun, Wegner, Annika, Rosenberger, Friederike, Dreger, Peter, Luft, Thomas, and Wiskemann, Joachim
- Subjects
STEM cell transplantation ,RESISTANCE training ,INTERVAL training ,HIGH-intensity interval training ,EXERCISE therapy ,PHYSICAL mobility ,PATIENT reported outcome measures - Abstract
Physical capacity prior allogeneic stem cell transplantation (allo-HCT) has been shown as a relevant prognostic factor for survival after transplant. Therefore, we evaluated feasibility and preliminary efficacy of a high-intensity interval training (HIIT) and moderate to high-intensity resistance exercise (RE) to increase physical capacity in patient's prior allo-HCT. In this multicentre single arm pilot study, a supervised exercise program was performed twice weekly for 4–12 weeks prior allo-HCT, depending on the individual time remaining. Outcomes were feasibility (recruitment, adherence, safety), physical capacity (cardiorespiratory fitness [VO2peak], muscle strength) and patient reported outcomes (physical functioning, fatigue). Thirty patients were intended, 16 could be included, and 14 completed post intervention assessment (75% male, 55 ± 11 years). The study was stopped early due to a low recruitment rate. Nine patients (64%) reached the initial minimum planned number of eight exercise sessions. Individual adherence was high with 92% for HIIT and 85% for RE. 87% of all performed exercise sessions were completed without complaints and VO2peak increased significantly from 20.4 to 23.4 ml/kg/min. The low recruitment rate suggests that initiation of the intervention concept immediately before allo-HCT is feasible only in a small number of patients. In particular, the timeframe directly prior allo-HCT seems too short for exercise interventions, although the exercise program was designed to improve outcomes in a very short time frame. HIIT and RE were feasible, effective and well accepted by the included patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation.
- Author
-
Korell, Felix, DeFilipp, Zachariah, Schreck, Nicholas, Luft, Thomas, Mau, Marcela V., Benner, Axel, Dreger, Peter, Chen, Yi-Bin, and Müller-Tidow, Carsten
- Subjects
STEM cell transplantation ,SEPSIS ,HEMATOPOIETIC stem cell transplantation - Abstract
Patient numbers for EASIX calculation are listed in following order (no neutropenic fever or sepsis / neutropenic fever without sepsis/neutropenic fever with sepsis) for the different timepoints: prior conditioning n = 125/200/27, day-3 n = 85/159/23, day 0 n = 84/159/23, day 3 n = 86/157/23, day 5 n = 87/153/22, day 7 n = 89/157/22, day 14 n = 108/161/20, day 21 n = 119/185/21, day 28 n = 120/194/17. As numbers of patients with sepsis were still small, these results warrant confirmation in larger multicenter trials with more sepsis patients. Sepsis patients were subgrouped by no neutropenic fever or sepsis, and neutropenic fever without and with sepsis. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
6. Statin‐based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.
- Author
-
Pabst, Caroline, Schreck, Nicholas, Benner, Axel, Hegenbart, Ute, Schönland, Stefan, Radujkovic, Aleksandar, Schmitt, Michael, Müller‐Tidow, Carsten, Orsatti, Laura, Dreger, Peter, and Luft, Thomas
- Subjects
STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,ENDOTHELIUM diseases ,INDOLEAMINE 2,3-dioxygenase ,ADVERSE health care events ,ENZYME metabolism - Abstract
Background: Allogeneic haematopoietic stem cell transplantation (alloSCT) often remains the only curative therapy for hematologic malignancies. Although the management of transplant‐associated adverse events considerably improved over the last decades, nonrelapse mortality (NRM) remains a challenge, and endothelial dysfunction was identified as a major contributor to NRM. Methods: Statin‐based endothelial prophylaxis (SEP) has been implemented in the standard of care in our transplant centre to reduce NRM caused by endothelial injury. Here, we retrospectively analysed the impact of SEP on clinical outcome in a cohort of 347 alloSCT patients. Results: SEP (n = 209) was associated with significantly reduced NRM (hazard ratio 0.61, 95% CI 0.38–0.96) and better overall survival (OS) after acute graft‐versus‐host disease (HR 0.59, 95% CI 0.37–0.93). Subgroup analyses showed that the NRM benefit was mainly found in patients with an intermediate endothelial activation and stress index (EASIX), while relapse risk was not affected. On day 100 post‐alloSCT, patients receiving SEP had significantly higher levels of the rate‐limiting enzyme of tryptophan metabolism, indoleamine 2,3‐dioxygenase (IDO), higher kynurenine to tryptophan ratios as a proxy of IDO activity and tended to have lower levels of the endothelial injury marker ST2 (p =.055). No significant differences in interferon‐gamma or IL18 levels were observed. These biomarker signatures suggest that the beneficial effects of SEP might be mediated by both endothelial protection and immunomodulation. Conclusions: Together, these data suggest that SEP improves NRM and OS post‐alloSCT in particular in patients with intermediate endothelial risk and provide first mechanistic clues about its potential mode of action. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Improving distributed collaboration for the development of advanced systems.
- Author
-
Duehr, Katharina, Luft, Thomas, Vierbacher, David, Ebner, Lukas, and Albers, Albert
- Subjects
CORPORATE culture ,ORGANIZATIONAL change ,TEAMS in the workplace ,LEADERSHIP ,QUALITATIVE research - Abstract
Effective and efficient distributed collaboration is essential for the development of advanced systems. This contribution investigates the effects of the application of a method that supports improvement in distributed collaboration in the development of advanced systems at Voith Turbo. Furthermore, it will be examined, whether the improvement of distributed collaboration has an influence on the organizational culture. In total, nine improvement potentials in distributed collaboration were derived. In total, nine improvement potentials in distributed collaboration were identified and addressed through the implementation of measures. Subsequently, the effects of the implemented improvement measures were evaluated by qualitatively, quantitatively, subjective and objective data. Based on that, new potentials were derived. Finally, the results show that improving distributed collaboration positively influences the organizational culture. Iterative and continuous focus on good collaboration and the immediate evaluation ensures an improvement in collaboration and a gradual change in organizational culture. [ABSTRACT FROM AUTHOR]
- Published
- 2022
8. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.
- Author
-
Raj, Kavita, Eikema, Dirk-Jan, Sheth, Vipul, Koster, Linda, de Wreede, Liesbeth C., Blaise, Didier, Di Grazia, Carmela, Koc, Yener, Potter, Victoria, Chevallier, Patrice, Lopez- Corral, Lucia, Wu, Depei, Mielke, Stephan, Maertens, Johan, Meijer, Ellen, Huynh, Anne, Passweg, Jakob, Luft, Thomas, Pérez-Simón, Jose Antonio, and Ciceri, Fabio
- Subjects
MYELODYSPLASTIC syndromes ,PROGRESSION-free survival ,SIBLINGS ,OVERALL survival - Abstract
Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p < 0.001). Two-year overall survival (OS) and PFS (progression free survival) with MSD were significantly better at 58% compared with 50%, p ≤ 0.001, and 51% vs 47%, p = 0.029, with a HD. Relapse at 2 years was lower with a HD 23% than with MSD 29% (p = 0.016). Non relapse mortality (NRM) was higher with HD in the first 6 months post-transplant [HR 2.59 (1.5–4.48) p < 0.001] and was also higher at 2 years being 30% for HD and 20% for MSD, p ≤ 0.001. The incidence of acute GVHD grade II-IV and III–IV at 100 days was comparable for MSD and HD, however, chronic GVHD at 2 years was significantly higher with MSD being 44% vs 32% for HD (p < 0.001). After multivariable analysis, OS and primary graft failure were significantly worse for HD particularly before 6 months [HR 1.93(1.24–3.0)], and HR [3.5(1.5–8.1)]. The median age of HD 37 (IQR 30–47) years was significantly lower than sibling donors 56 (IQR 49–62 years) p < 0.001. However, there was no effect on NRM, relapse or PFS. This data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it's use when no better donor is available. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) - design and rational of a randomized controlled trial.
- Author
-
Bujan Rivera, Janina, Kühl, Rea, Zech, Ulrike, Hendricks, Anne, Luft, Thomas, Dreger, Peter, Friedmann-Bette, Birgit, Betz, Theresa-Maria, and Wiskemann, Joachim
- Abstract
Background: Graft-versus-host disease (GvHD) remains a major complication and limitation to successful allogeneic hematopoietic stem cell transplantation. Treatment of GvHD is challenging due to its heterogeneous nature of presentation, with steroids remaining the established first-line treatment. Long-term doses of systemic corticosteroids have many well-known side-effects including muscle atrophy. Despite the fact that reports in non-cancer clinical populations treated with glucocorticoids demonstrated that resistance training can reverse atrophy and weakness, no RCT has evaluated the potential of resistance training on preventing the disease- and treatment-induced loss of skeletal muscle mass and function in GvHD patients yet. In this context, ensuring adequate nutrition is important as protein deprivation may accelerate the wasting process. As GvHD patients are commonly found to be malnourished, nutritional medical care should be considered when investigating the effect of exercise in GvHD patients. Therefore, the aim of the present "Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD" - Study (IRENE-G) is to evaluate the effects of resistance exercise in combination with nutritional endorsement on physical, nutritional and patient-reported outcomes in GvHD patients.Methods: IRENE-G is a 24-week prospective interventional RCT. One hundred twelve participants will be randomly allocated (1:1) to one of two arms: resistance exercise and nutritional optimization (experimental) vs. nutritional optimization only (control). Participants in the experimental group will engage in a supervised, progressive moderate-to-high intensity resistance training that is consistent with exercise guidelines for cancer patients, while additionally receiving nutritional support/therapy. Subjects of the control group solely receive nutritional support/therapy based on individual needs. Participants will be assessed at baseline, at 8, 16, 24 weeks for physical performance and various physiological, nutritional and patient-reported outcomes. Follow-up will be 6 months after intervention completion.Discussion: To our knowledge, this will be the first RCT to assess and compare the effects of a resistance intervention supplemented by nutritional support/therapy against nutritional support only on various health-related outcomes in GvHD patients. The study will contribute to our understanding of the value of exercise and nutritional endorsement in counteracting the negative consequences of GvHD and its treatment.Trial Registration: ClinicalTrials.gov : NCT05111834 . Registered 8 November 2021 - Retrospectively registered. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study.
- Author
-
Korell, Felix, Penack, Olaf, Mattie, Mike, Schreck, Nicholas, Benner, Axel, Krzykalla, Julia, Wang, Zixing, Schmitt, Michael, Bullinger, Lars, Müller-Tidow, Carsten, Dreger, Peter, and Luft, Thomas
- Subjects
CELLULAR therapy ,CYTOKINE release syndrome ,CHIMERIC antigen receptors ,COHORT analysis ,PROGNOSIS - Abstract
Background: Endothelial dysfunction is associated with two main complications of chimeric antigen receptor T (CAR-T) cell therapy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This study evaluates the Endothelial Activation and Stress Index (EASIX) as a prognostic marker for high-grade CRS and ICANS in patients treated with CD19-directed CAR-T cells. Methods: In this retrospective study, a training cohort of 93 patients from the ZUMA-1 trial and a validation cohort of 121 patients from two independent centers (University Hospital Heidelberg, Charité University Medicine Berlin) were investigated. The primary objective was to assess the predictive capacity of EASIX measured immediately before the start of lymphodepletion (EASIX-pre) for the occurrence of grade ≥3 CRS and/or ICANS. To explore a possible endothelial link, serum levels of endothelial stress markers (angiopoietin-2, suppressor of tumorigenicity-2, soluble thrombomodulin, and interleukin-8) were determined before lymphodepletion and on day 7 after CART infusion in the validation cohort (n = 47). Results: The prognostic effect of EASIX-pre on grade ≥3 CRS and/or ICANS was significant in the training cohort [OR 2-fold increase 1.72 (1.26–2.46)] and validated in the independent cohort. An EASIX-pre cutoff >4.67 derived from the training cohort associated with a 4.3-fold increased odds ratio of severe CRS/ICANS in the independent cohort. Serum endothelial distress markers measured on day+7 correlated with EASIX-pre and associated with severe complications. Conclusions: EASIX-pre is a powerful predictor of severe CRS/ICANS after CD19-directed CART therapy and might be used as a basis for risk-adapted prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Submyeloablative total body irradiation‐based conditioning and allogeneic stem cell transplantation in high‐risk myeloma with early progression after up‐front autologous transplantation.
- Author
-
Mai, Elias K., Schmitt, Thomas, Radujkovic, Aleksandar, König, Laila, Goldschmidt, Hartmut, Ho, Anthony D., Luft, Thomas, Müller‐Tidow, Carsten, Dreger, Peter, Hegenbart, Ute, and Schönland, Stefan O.
- Subjects
STEM cell transplantation ,AUTOTRANSPLANTATION ,ACUTE diseases ,MULTIPLE myeloma ,HEMATOPOIETIC stem cell transplantation ,GRAFT versus host disease - Abstract
Finally, other potential treatment options to reduce relapse/progression post alloSCT include post-transplantation cyclophosphamide (ptCy). Keywords: myeloma therapy; stem cell transplantation; cytogenetics EN myeloma therapy stem cell transplantation cytogenetics 244 248 5 12/27/21 20220101 NES 220101 Treatment of patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (autoSCT) remains challenging. Consequently, a future goal in MM therapy is to combine modern treatment concepts and alloSCT in suitable patients to reduce disease burden and enhance disease control in patients with relapsed high-risk MM. Details on re-induction treatment and response rates prior to alloSCT, engraftment and post alloSCT response rates, maintenance therapy, donor lymphocyte infusions (DLI) and relapse therapies are shown in Table I. The median age at alloSCT was 50 (range 34-64) years. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
12. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT
- Author
-
Shimoni, Avichai, Robin, Marie, Iacobelli, Simona, Beelen, Dietrich, Mufti, Ghulam J., Ciceri, Fabio, Bethge, Wolfgang, Volin, Liisa, Blaise, Didier, Ganser, Arnold, Luft, Thomas, Chevallier, Patrice, Schwerdtfeger, Rainer, Koster, Linda, de Witte, Theo, Kröger, Nicolaus, Nagler, Arnon, and Yakoub-Agha, Ibrahim
- Subjects
HEMATOPOIETIC stem cell transplantation ,MYELODYSPLASTIC syndromes ,TREATMENT effectiveness ,MULTIVARIATE analysis - Abstract
Summary: Allogeneic haematopoietic‐cell transplantation (allo‐HCT) is a potentially curative therapy for high‐risk myelodysplastic syndrome (MDS). Reduced‐intensity conditioning (RIC) is usually associated with lower non‐relapse mortality (NRM), higher relapse rate and similar overall‐survival (OS) as myeloablative‐conditioning (MAC). Fludarabine/treosulfan (FT) is a reduced‐toxicity regimen with intense anti‐leukaemia activity and a favourable toxicity profile. We investigated post‐transplant outcomes in 1722 MDS patients following allo‐HCT with FT (n = 367), RIC (n = 687) or MAC (n = 668). FT and RIC recipients were older than MAC recipients, median age 59, 59 and 51 years, respectively (P < 0·001) but other disease characteristics were similar. The median follow‐up was 64 months (1–171). Five‐year relapse rates were 25% (21–30), 38% (34–42) and 25% (22–29), after FT, RIC and MAC, respectively, (P < 0·001). NRM was 30% (25–35), 27% (23–30) and 34% (31–38, P = 0·008), respectively. Five‐year OS was 50% (44–55), 43% (38–47), and 43% (39–47), respectively (P = 0·03). In multivariate analysis, FT was associated with a lower risk of relapse (HR 0·55, P < 0·001) and better OS (HR 0·72, P = 0·01). MAC was associated with higher NRM (HR 1·44, P = 0·001). In conclusion, FT is associated with similar low relapse rates as MAC and similar low NRM as RIC, resulting in improved OS. FT may be the preferred regimen for allo‐HCT in MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
- Author
-
Derigs, Patrick, Radujkovic, Aleksandar, Schubert, Maria-Luisa, Schnitzler, Paul, Schöning, Tilman, Müller-Tidow, Carsten, Hegenbart, Ute, Schönland, Stefan O., Luft, Thomas, Dreger, Peter, and Schmitt, Michael
- Subjects
HEMATOPOIETIC stem cell transplantation ,CYTOMEGALOVIRUSES ,OVERALL survival ,CYTOMEGALOVIRUS diseases ,PREVENTIVE medicine - Abstract
Morbidity and mortality after allogeneic hematopoietic cell transplantation (alloHCT) are still essentially affected by reactivation of cytomegalovirus (CMV). We evaluated 80 seropositive patients transplanted consecutively between March 2018 and March 2019 who received letermovir (LET) prophylaxis from engraftment until day +100 and retrospectively compared them with 80 patients without LET allografted between January 2017 and March 2018. The primary endpoint of this study was the cumulative incidence (CI) of clinically significant CMV infection (CS-CMVi) defined as CMV reactivation demanding preemptive treatment or CMV disease. With 14% CI of CS-CMVi at day +100 (11 events) was significantly lower in the LET cohort when compared to the control group (33 events, 41%; HR 0.29; p < 0.001). Whereas therapy with foscarnet could be completely avoided in the LET group, 7 out of 80 patients in the control cohort received foscarnet, resulting in 151 extra in-patient days for foscarnet administration (p = 0.002). One-year overall survival was 72% in the control arm vs 84% in the LET arm (HR 0.75 [95%CI 0.43–1.30]; p < 0.306). This study confirms efficacy and safety of LET for prophylaxis of CS-CMVi after alloHCT in a real-world setting, resulting in a significant patient benefit by reducing hospitalization needs and exposure to potentially toxic antiviral drugs for treatment of CMV reactivation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.
- Author
-
Luft, Thomas, Wendtner, Clemens-Martin, Kosely, Florentina, Radujkovic, Aleksandar, Benner, Axel, Korell, Felix, Kihm, Lars, Bauer, Matthias F., Dreger, Peter, and Merle, Uta
- Subjects
SARS-CoV-2 ,COVID-19 ,STEM cell transplantation - Abstract
Background: The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. Methods: SARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions. Results: EASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha. Conclusion: EASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation.
- Author
-
Korell, Felix, Schreck, Nicholas, Müller-Tidow, Carsten, Dreger, Peter, Luft, Thomas, the Taskforce allogeneic Stem Cell Transplantation, University Hospital Heidelberg, Liebregts, Tobias, Schönland, Stefan, Hegenbart, Ute, Radujkovic, Aleksandar, Schmitt, Michael, and Benner, Axel
- Abstract
Patients who developed sepsis had higher median EASIX values before conditioning (EASIX-pre) and at any later time point until day+28 irrespective of pathogen detection (Fig. Using this cut-off for multivariable Cox regression analysis in the validation cohort, we observed a cause-specific HR of 16.1 (7.0-36.9) for EASIX > 2.32 with respect to time to sepsis, corresponding to 7/462 sepsis events (1.5%) in the low-risk group vs 40/172 (23%) in the high-risk group (Suppl. 1 A Box plot comparison of EASIX before and after alloSCT in patients who did or did not develop sepsis within 50 days after transplantation (full cohort). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
16. Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.
- Author
-
Dai, Hao, Rachakonda, Sivaramakrishna P., Penack, Olaf, Blau, Igor W., Blau, Olga, Radujkovic, Aleksandar, Müller-Tidow, Carsten, Dreger, Peter, Kumar, Rajiv, and Luft, Thomas
- Abstract
Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9–11 SNPs as well as peri-transplant CXCL9–11 serum levels were analyzed in 688 patients without (training cohort; n = 287) or with statin-based endothelial protection cohort (n = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort (n = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33–4.64, P = 0.004) and validation cohort (HR 2.95, 95% CI 1.56–5.58, P = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 (P < 0.001) and rs884004 (P < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10–1.73, P = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation.
- Author
-
Limbach, Matthias, Kuehl, Rea, Dreger, Peter, Luft, Thomas, Rosenberger, Friederike, Kleindienst, Nikolaus, Friedmann-Bette, Birgit, Bondong, Andrea, Bohus, Martin, and Wiskemann, Joachim
- Subjects
CARDIOPULMONARY fitness ,STEM cell transplantation ,EXERCISE tests ,PHYSICAL activity ,BODY mass index - Abstract
Purpose: Cardiorespiratory fitness (CRF) seems to be prognostic prior to allogeneic stem cell transplantation (allo-HSCT). Influencing factors of CRF in allo-HSCT candidates have not been studied so far. Aim was to identify potentially influencing factors on CRF. Methods: To assess CRF, a maximal cardiopulmonary exercise test (CPET) was performed on average 2.6 ± 7.2 days prior to admission. A regression analysis was conducted, with the following predictors: gender, age, body mass index (BMI), time between last therapy and allo-HSCT (t_Therapies), number of cardiotoxic therapies (n_Cardiotox), number of transplantations (n_Transplantations), comorbidity index (HCT-CI), hemoglobin level of the last 3 months (area under the curve), and physical activity. Results: A total of 194 patients performed a CPET. VO
2peak was significantly reduced compared with reference data. In total, VO2peak was 21.4 ml/min/kg (− 27.5%, p < 0.05). Men showed a significant larger percentage difference from reference value (− 29.1%, p < 0.05) than women (− 24.4%). VO2peak was significantly (p < 0.05) influenced by age (β = − 0.11), female gender (β = − 3.01), BMI (β = − 0.44), n_Cardiotox (β = − 0.73), hemoglobin level (β = 0.56), and physical activity prior to diagnosis (β = 0.10). Conclusions: Our study demonstrates a decreased CRF indicating the potential need of prehabilitative exercise. We revealed some influencing factors on CRF. Those patients could benefit the most from exercise. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
- Author
-
Radujkovic, Aleksandar, Hegenbart, Ute, Müller-Tidow, Carsten, Herfarth, Klaus, Dreger, Peter, and Luft, Thomas
- Subjects
CHRONIC leukemia ,TOTAL body irradiation ,ACUTE myeloid leukemia ,GRAFT versus host disease ,IMMUNOSUPPRESSION ,THERAPEUTIC use of antimetabolites ,TREATMENT of chronic myeloid leukemia ,ACUTE myeloid leukemia treatment ,HOMOGRAFTS ,MELPHALAN ,MYCOPHENOLIC acid ,ANTIVIRAL agents ,RETROSPECTIVE studies ,ANTILYMPHOCYTIC serum ,PROGNOSIS ,METHOTREXATE ,ANTIMETABOLITES ,KAPLAN-Meier estimator ,SECONDARY primary cancer ,HEMATOPOIETIC stem cell transplantation ,IMMUNOSUPPRESSIVE agents ,RADIOTHERAPY ,BUSULFAN ,T cells ,PROPORTIONAL hazards models ,THERAPEUTICS - Abstract
This retrospective single-center analysis studied the impact of the conditioning and the graft-versus-host disease (GVHD) prophylaxis on outcome in unselected patients allografted for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) secondary to documented prior CMML. A total of 44 patients (median age 61 years) allografted between 2002 and 2019 in our institution were analyzed. Fifteen patients had secondary AML. The conditioning regimen was fractionated 6-8 Gy total body irradiation (TBI) in combination with fludarabine in 33 (75%) patients. Eleven patients (25%) received alkylator-based conditioning therapy without TBI. For GVHD prophylaxis, a calcineurin inhibitor (CNI) backbone in combination with methotrexate (MTX) or mycophenolate mofetil (MMF) was applied in 21 and 23 patients, respectively. All patients allografted from an unrelated donor (UD) received antithymocyte globuline. In univariate analysis of the entire cohort, TBI-based conditioning and MMF-containing immunosuppression were associated with improved leukemia-free survival (LFS, HR 0.16, P < 0.001 and HR 0.41, P = 0.030, respectively). After stratification according to conditioning and GVHD prophylaxis into four groups (TBI-MMF [n = 17], TBI-MTX [n = 16], alkylator-MMF [n = 6], alkylator-MTX [n = 5]), TBI-MMF was associated with improved overall survival (OS) and LFS (P = 0.001 and P < 0.001, respectively). Patient and disease characteristics did not differ between the groups. The associations of TBI-based conditioning and MMF with prolonged LFS were observed across the CMML (n = 29), secondary AML (n = 15), and UD allograft (n = 34) subgroups. In summary, our study suggests that allografting based on intermediate-dose TBI conditioning and MMF-containing GVHD prophylaxis is associated with increased disease control in CMML. Larger (registry-based) studies are warranted to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. EASIX for prediction of survival in lower-risk myelodysplastic syndromes.
- Author
-
Merz, Almuth, Germing, Ulrich, Kobbe, Guido, Kaivers, Jennifer, Jauch, Anna, Radujkovic, Aleksandar, Hummel, Manuela, Benner, Axel, Merz, Maximilian, Dreger, Peter, and Luft, Thomas
- Subjects
MYELODYSPLASTIC syndromes ,CARDIOVASCULAR diseases ,PATIENTS ,ENDOTHELIAL cells ,CYTOGENETICS - Abstract
Patients with myelodysplastic syndromes (MDS) are at risk of early death from cardiovascular complications due to the link between clonal hematopoiesis and endothelial dysfunction. EASIX (Endothelial Activation and Stress Index) has been established to predict endothelial complications after allogeneic transplantation. We investigated the impact of EASIX measured at first diagnosis on survival of patients with lower- and higher-risk MDS (no allogeneic transplantation) in two independent institutions: n = 192 (training cohort) and n = 333 (validation cohort). Serum markers of endothelial cell distress were measured and correlated to EASIX. While no effects of EASIX on survival were observed in higher-risk patients, EASIX was associated with shorter survival in patients with lower-risk MDS in both cohorts (univariate: Cohort I: hazard ratio (HR): 1.46; 95% confidence interval (CI) 1.24–1.71; p-value < 0.001/Cohort II: HR 1.31 [1.17–1.48]; p-value < 0.001). Multivariate Cox regression analysis and prediction error analyses confirmed that EASIX remained a significant predictor of survival after adjustment for age, sex, cytogenetic abnormalities and bone marrow blasts in lower-risk patients. The model of the training cohort could be validated. Serum levels of Angiopioetin-2 correlated significantly with EASIX. We introduce EASIX as an easily accessible and independent predictor for survival in patients with lower-risk MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.
- Author
-
Ni, Ming, Wang, Lei, Yang, Mingya, Neuber, Brigitte, Sellner, Leopold, Hückelhoven-Krauss, Angela, Schubert, Maria-Luisa, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Wuchter, Patrick, Chen, Bao-an, Eckstein, Volker, Krüger, William, Yerushalmi, Ronit, Beider, Katia, Nagler, Arnon, Müller-Tidow, Carsten, Dreger, Peter, and Schmitt, Michael
- Subjects
KILLER cells ,GRAFT versus host disease ,PHOTOPHORES ,HEMATOPOIETIC stem cells ,CYTOKINES - Abstract
CD56
bri natural killer (NK) cells play an important role in the pathogenesis of graft-vs. -host disease (GVHD) and immune defense in the early period after allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP) as an immunomodulating therapy has been widely used for GVHD treatment. However, the mechanism of action of ECP still remains to be elucidated, particularly the influence of ECP on NK cells. Thirty-four patients with steroid-refractory/resistant acute GVHD (aGVHD) ≥ °II and moderate to severe chronic GVHD (cGVHD) received ECP therapy. Patient samples obtained during intensive and long-term treatment were analyzed. Immunomonitoring with respect to cell phenotype and function was performed on rested peripheral blood mononuclear cells (PBMCs) using multiparametric flow cytometry. NK activity in terms of cytokine release was analyzed by intracellular cytokine staining after co-culture with K562 cells. Moreover, the proliferative capacity of NK cells, CD4+ , and CD8+ T cells was determined by carboxyfluorescein succinimidyl ester (CFSE) staining. Clinically, 75% of aGVHD and 78% of cGVHD patients responded to ECP therapy. Moreover, our data show that aGVHD, cGVHD patients and healthy donors (HDs) present distinct NK patterns: aGVHD patients have a higher frequency of CD56bri NK subsets with stronger NKG2D and CD62L expression, while CD56− CD16+ NK cells with higher expression of CD57 and CD11b stand out as a signature population for cGVHD. ECP therapy could significantly decrease CD56bri CD16− NK cells with shifting the quality from a cytotoxic to a regulatory pattern and additionally mature CD56dim NK cells via upregulation of CD57 in complete responding aGVHD patients. Moreover, ECP could keep the anti-viral and anti-leukemic effects intact via maintaining specialized anti-viral/leukemic CD57+ NKG2C+ CD56dim NK cells as well as remaining the quality and quantity of cytokine release by NK cells. The proliferative capacity of effector cells remained constant over ECP therapy. In conclusion, ECP represents an attractive option to treat GVHD without compromising anti-viral/leukemic effects. Shaping of CD56bri NK cell compartment by downregulating the cytotoxic subset while upregulating the regulatory subset contributes to the mechanisms of ECP therapy in aGVHD. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.
- Author
-
Wang, Lei, Ni, Ming, Hückelhoven-Krauss, Angela, Sellner, Leopold, Hoffmann, Jean-Marc, Neuber, Brigitte, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Kleist, Christian, Sill, Martin, Chen, Bao-an, Wuchter, Patrick, Eckstein, Volker, Krüger, William, Hilgendorf, Inken, Yerushalmi, Ronit, Nagler, Arnon, Müller-Tidow, Carsten, and Ho, Anthony D.
- Abstract
Graft-vs.-host disease (GvHD), a severe complication of allogeneic hematopoietic stem cell transplantation, significantly affects the post-transplant morbidity and mortality. Systemic steroids remain the gold standard for the initial management of GvHD. However, up to 60% of patients will not sufficiently respond to steroids. Extracorporeal photopheresis (ECP), a cell-based immunotherapy, has shown good clinical results in such steroid-refractory/resistant GvHD patients. Given its immunomodulatory, but not global immunosuppressive and steroid-sparing capacity, ECP constitutes an attractive option. In the case of GvHD, the balance of immune cells is destroyed: effector cells are not any longer efficiently controlled by regulatory cells. ECP therapy may restore this balance. However, the precise mechanism and the impact of ECP on anti-viral/anti-leukemic function remain unclear. In this study, 839 ECP treatments were performed on patients with acute GvHD (aGvHD) and chronic GvHD (cGvHD). A comprehensive analysis of effector and regulatory cells in patients under ECP therapy included multi-parametric flow cytometry and tetramer staining, Luminex
TM -based cytokine, interferon-γ enzyme-linked immunospot, and chromium-51 release assays. Gene profiling of myeloid-derived suppressor cells (MDSCs) was performed by microarray analysis. Immunologically, modulations of effector and regulatory cells as well as proinflammatory cytokines were observed under ECP treatment: (1) GvHD-relevant cell subsets like CD62L+ NK cells and newly defined CD19hi CD20hi B cells were modulated, but (2) quantity and quality of anti-viral/anti-leukemic effector cells were preserved. (3) The development of MDSCs was promoted and switched from an inactivated subset (CD33− CD11b+ ) to an activated subset (CD33+ CD11b+ ). (4) The frequency of Foxp3+ CD4+ regulatory T cells (Tregs) and CD24+ CD38hi regulatory B cells was considerably increased in aGvHD patients, and Foxp3+ CD8+ Tregs in cGvHD patients. (5) Proinflammatory cytokines like IL-1β, IL-6, IL-8, and TNF-α were significantly reduced. In summary, ECP constitutes an effective immunomodulatory therapy for patients with steroid-refractory/resistant GvHD without impairment of anti-viral/leukemia effects. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. CD7 is expressed on a subset of normal CD34‐positive myeloid precursors.
- Author
-
Kriegsmann, Katharina, Löffler, Harald, Eckstein, Volker, Schulz, Renate, Kräker, Sandra, Braun, Ute, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Dreger, Peter, Krämer, Alwin, Ho, Anthony D., Müller‐Tidow, Carsten, and Hundemer, Michael
- Subjects
TUMORS ,FLOW cytometry ,CHIMERISM ,STEM cell transplantation ,BONE marrow - Abstract
Abstract: Objective: To improve monitoring of myeloid neoplasms by flow cytometry‐based minimal residual disease (MRD) analysis, we analyzed the significance of leukemia‐associated immunophenotype (LAIP) markers in 44 patients. Methods: In a pilot study cohort, peripheral blood or bone marrow samples from 13 patients with myeloid neoplasms and one case of B lymphoblastic leukemia in complete hematologic remission after allogeneic bone marrow or stem cell transplantation were subjected to selection for leukemia‐specific phenotypes by fluorescence‐activated cell sorting using individual marker combinations, followed by PCR‐based chimerism analysis. Results: The feasibility of this method could be demonstrated, with selection being successful in 12 cases, including two cases where mixed chimerism was found exclusively in sorted cells. Interestingly, four specimens displayed full donor chimerism in cells expressing the presumably aberrant combination CD34
+ /CD7+ . Further analyses, including assessment of an independent cohort of 25 patients not affected by neoplastic bone marrow infiltration, revealed that normal myeloid precursors usually include a population coexpressing CD34, CD13, CD33, and CD7. Conclusion: We conclude that the combination CD34+ /CD7+ might not be suitable as an LAIP for MRD diagnostics and that a subset of normal myeloid precursors in the bone marrow expresses CD7. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
- Author
-
Rohlfing, Sarah, Dietrich, Sascha, Witzens-Harig, Mathias, Hegenbart, Ute, Schönland, Stefan, Luft, Thomas, Ho, Anthony D., and Dreger, Peter
- Subjects
STEM cell transplantation ,T-cell lymphoma ,CANCER chemotherapy ,B cells ,RITUXIMAB ,ANTINEOPLASTIC agents ,AUTOGRAFTS ,COMBINED modality therapy ,COMPARATIVE studies ,HEMATOPOIETIC stem cell transplantation ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,EVALUATION research ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,DISEASE progression ,SALVAGE therapy ,KAPLAN-Meier estimator ,CONFOUNDING variables ,THERAPEUTICS - Abstract
The role of autologous stem cell transplantation (autoSCT) as consolidating treatment for peripheral T-cell lymphoma (PTCL) is unsettled. The aim of this analysis was to investigate the impact of autoSCT in the upfront setting by intent-to-treat and to study salvage strategies after relapse. Retrospective follow-up of all patients aged 18-70 years and treated at our institution for ALK-PTCL diagnosed between 2001 and 2014. Of 117 eligible patients, diagnosis was PTCL-NOS in 34, ALCL ALK- in 31, AITL in 28, and other PTCL in 24 patients. Disregarding 20 patients who received first-line treatment externally, upfront autoSCT was not intended in 34 due to comorbidity, higher age, low IPI, physician's decision or unknown reasons (nITT), while intent-to-transplant (ITT) was documented in 63 patients. ITT was not associated with significant benefits for 5-year progression-free survival (PFS) and overall survival (OS) with 46 and 23% in the ITT group vs. 42 and 25% in the nITT group, even after multivariate adjustment for confounders. Altogether, 91 of all 117 patients relapsed or progressed. Thirty-one patients managed to proceed to salvage allografting and achieved a 5-year OS of 52%. In contrast, all 7 patients receiving salvage autoSCT relapsed and died, and only 3 of the 51 patients not eligible for SCT salvage survived. In this study, a significant benefit of intending first-line autoSCT over non-transplant induction in patients with ALK-PTCL did not emerge. Most patients fail first-line treatment and have a poor outlook if salvage alloSCT cannot be performed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS Cohort.
- Author
-
Auer, Michael, Hegen, Harald, Luft, Thomas, Bsteh, Gabriel, Fogdell-Hahn, Anna, Loercher, Amy, and Deisenhammer, Florian
- Subjects
MULTIPLE sclerosis diagnosis ,MULTIPLE sclerosis risk factors ,BLOOD serum analysis ,COTININE ,IMMUNOGLOBULINS ,INTERFERON beta 1b ,EPIDEMIOLOGY - Abstract
Previous epidemiologic studies showed an increased risk of neutralizing antibody (NAb) development against Interferon beta in multiple sclerosis patients who smoke. Cotinine is an easily detectable metabolite of nicotine and, therefore, can be used as an objective surrogate marker for smoking status. We measured cotinine levels in NAb-positive and NAb-negative patients to find a potential association of nicotine consumption and NAb development. Cotinine was measured in 37 patients with known smoking status and in 123 patients with unknown smoking status, all of whom were routinely tested for NAb. Cotinine was detected by an enzyme-linked immunosorbent assay, inhibition assay. We compared cotinine levels by NAb status and tested for the strength of association between cotinine and NAb status. We found a discrepancy between smoking status stated by patients and status defined by cotinine levels in 7 of 37 patients. In both cohorts, together with and without previously known smoking status ( n = 160), we found 34% and 39% smokers, respectively, as defined by cotinine levels in NAb-negative and NAb-positive patients ( P = 0.511). In our analysis, smoking was not associated with higher risk of NAb development. Moreover, smoking habits stated by patients do not always correlate with cotinine levels. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
- Author
-
Radujkovic, Aleksandar, Dietrich, Sascha, Andrulis, Mindaugas, Benner, Axel, Longerich, Thomas, Pellagatti, Andrea, Nanda, Kriti, Giese, Thomas, Germing, Ulrich, Baldus, Stefan, Boultwood, Jacqueline, Ho, Anthony D., Dreger, Peter, and Luft, Thomas
- Abstract
We tested the hypothesis that proliferative activity of hematopoietic stem cells has impact on survival in newly diagnosed patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML). RNA expression profiles of CD34
+ cells were analyzed in 125 MDS patients and compared to healthy controls. Prognostic impact on overall survival (OS) of mRNA proliferation signatures established for solid tumor cells was analyzed retrospectively. For validation on the protein level, immunofluorescence and immunohistochemistry analyses in bone marrow (BM) biopsies were performed, and an independent cohort of 223 MDS and secondary AML patients was investigated. Lower proliferative activity correlated with the expression of cyclin-dependent kinase inhibitor 1C ( CDKN1C) and with shorter OS ( p < 0.001). In multivariable analysis, higher CDKN1C expression was associated with worse OS ( p = 0.02). On the BM level, a total of 84 (38%) patients showed CDKN1C protein expression before start of treatment. Patient, disease and treatment characteristics did not differ between CDKN1C-positive and -negative patients. Positive CDKN1C BM status was associated with shorter OS in multivariable analysis (HR 1.54, p = 0.04). There was an interaction between CDKN1C BM status and subsequent treatment with negative impact on OS being most pronounced in patients receiving conventional cytotoxic chemotherapy ( n = 83, 2-year OS 30% versus 58%, p = 0.002). In conclusion, low-proliferative phenotype and CDKN1C expression were associated with shorter OS. CDKN1C protein expression in the BM of newly diagnosed, treatment-naïve MDS and secondary AML patients was identified as a prognostic factor for poor survival in patients treated with antiproliferative chemotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
26. Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation.
- Author
-
Dietrich, Sascha, Radujkovic, Aleksandar, Stölzel, Friedrich, Falk, Christine S., Benner, Axel, Schaich, Markus, Bornhäuser, Martin, Ehninger, Gerhard, Krämer, Alwin, Hegenbart, Ute, Ho, Anthony D., Dreger, Peter, and Luft, Thomas
- Published
- 2015
- Full Text
- View/download PDF
27. An Indicator-Based Process Monitoring Cockpit for Controlling and Enhancing Product Development Processes – An Industrial Case Study.
- Author
-
Luft, Thomas, Smoll, Simon, and Wartzack, Sandro
- Published
- 2013
- Full Text
- View/download PDF
28. Enhancing the Flow of Information in the PLM by Using Numerical DSMs – An Industrial Case Study.
- Author
-
Luft, Thomas, Bochmann, Johanna, and Wartzack, Sandro
- Published
- 2013
- Full Text
- View/download PDF
29. Real-time watercolor illustrations of plants using a blurred depth test.
- Author
-
Luft, Thomas and Deussen, Oliver
- Published
- 2006
- Full Text
- View/download PDF
30. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience.
- Author
-
Radujkovic, Aleksandar, Dietrich, Sascha, Bochtler, Tilmann, Krämer, Alwin, Schöning, Tilman, Ho, Anthony D., Dreger, Peter, and Luft, Thomas
- Subjects
ACUTE myeloid leukemia ,AZACITIDINE ,CYTARABINE ,BONE marrow ,FEBRILE neutropenia ,MULTIVARIATE analysis ,PATIENTS ,THERAPEUTICS - Abstract
We retrospectively analyzed and compared the efficacy and toxicity of azacitidine ( AZA) and low-dose cytarabine ( LD- Ara- C) in 65 palliative patients with acute myeloid leukemia ( AML) showing high bone marrow blast counts (≥30%) before start of treatment. Twenty-seven and 38 patients received AZA and LD- Ara- C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD- Ara- C group. AZA and LD- Ara- C were first-line treatment in 12 (44%) and 17 patients (45%), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15% (95% CI 8-22) and 13% (95% CI 7-19) in the AZA and LD- Ara- C groups, respectively, without statistically significant difference. In multivariate analysis ( n = 65), previous treatment ( HR 2.27, 95% CI 1.00-5.22, P = 0.05) and adverse cytogenetics ( HR 2.50, 95% CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
- Author
-
Radujkovic, Aleksandar, Luft, Thomas, Dreger, Peter, Ho, Anthony, Jens Zeller, W., Fruehauf, Stefan, and Topaly, Julian
- Subjects
TREATMENT of chronic myeloid leukemia ,NILOTINIB ,ALKYLATING agents ,STEM cell transplantation ,DRUG synergism - Abstract
Purpose: The prognosis of patients with advanced-phase chronic myeloid leukemia (CML) remains dismal despite the availability of targeted therapies and allogeneic stem cell transplantation (allo-SCT). Increasing the antileukemic efficacy of the pretransplant conditioning regimen may be a strategy to increase remission rates and duration. We therefore investigated the antiproliferative effects of nilotinib in combination with drugs that are usually used for conditioning: the alkylating agents mafosfamide, treosulfan, and busulfan. Methods: Drug combinations were tested in vitro in different imatinib-sensitive and imatinib-resistant BCR-ABL-positive cell lines. A tetrazolium-based MTT assay was used for the assessment and quantification of growth inhibition after exposure to alkylating agents alone or to combinations with nilotinib. Drug interaction was analyzed using the median-effect method of Chou and Talalay, and combination index (CI) values were calculated according to the classic isobologram equation. Results: Treatment of imatinib-sensitive, BCR-ABL-positive K562 and LAMA84 cells with nilotinib in combination with mafosfamide, treosulfan, or busulfan resulted in synergistic (CI < 1), additive (CI ~ 1), and predominantly antagonistic (CI > 1) effects, respectively. In imatinib-resistant K562-R and LAMA84-R cells, all applied drug combinations were synergistic (CI < 1) at higher growth inhibition levels. Conclusions: Our in vitro data warrant further investigation and may provide the basis for nilotinib-supplemented conditioning regimens for allo-SCT in advanced-phase CML. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Imatinib-supplemented myeloablative total-body irradiation/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia.
- Author
-
Radujkovic, Aleksandar, Dreger, Peter, Hegenbart, Ute, Buss, Eike C., Luft, Thomas, Ho, Anthony D., Fruehauf, Stefan, and Topaly, Julian
- Subjects
IMATINIB ,CHRONIC myeloid leukemia ,STEM cell transplantation ,PATIENTS - Abstract
A letter to the editor is presented which discusses the prospective studies on the effect of pretransplant imatinib in patients with blast crisis of chronic myeloid leukemia (BC-CML) after myeloablative allogeneic stem cell transplantation (allo-SCT).
- Published
- 2014
- Full Text
- View/download PDF
33. Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.
- Author
-
Schwarzbich, Mark-Alexander, Dai, Hao, Kordelas, Lambros, Beelen, Dietrich W., Radujkovic, Aleksandar, Müller-Tidow, Carsten, Dreger, Peter, and Luft, Thomas
- Subjects
ACUTE myeloid leukemia ,LEPTIN ,PEPTIDE hormones ,STEM cell transplantation ,ACUTE leukemia - Abstract
Weight loss and metabolic activity influence outcome after allogeneic stem cell transplantation (alloSCT). This study evaluates pre-conditioning Leptin, a peptide hormone involved in metabolism and immune homeostasis, as a prognostic factor for survival, relapse and non-relapse mortality (NRM) following alloSCT. Leptin serum levels prior to conditioning were determined in a cohort of patients transplanted for various hematologic malignancies (n = 524) and correlated retrospectively with clinical outcome. Findings related to patients with acute leukemia (AL) from this sample were validated in an independent cohort. Low pre-conditioning serum Leptin was an independent prognostic marker for increased risk of relapse (but not of NRM and overall mortality) following alloSCT for AL of intermediate and advanced stage (beyond first complete remission). Multivariate analysis revealed a hazard ratio (HR) for relapse of 0.75 per log2 increase (0.59–0.96, p = 0.020). This effect was similar in an independent validation cohort. Pre-conditioning serum Leptin was validated as a prognostic marker for early relapse by fitting the multivariate Cox model to the validation data. Pre-conditioning serum Leptin levels may serve as an independent prognostic marker for relapse following alloSCT in intermediate and advanced stage AL patients. Prospective studies are required to prove whether serum Leptin could be used for guiding nutritional intervention in patients with AL undergoing alloSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation.
- Author
-
Pabst, Caroline, Benning, Louise, Liebers, Nora, Janssen, Maike, Caille, Leandra, Speer, Claudius, He, Lixiazi, Schubert, Maria-Luisa, Simons, Laura, Hegenbart, Ute, Schönland, Stefan, Radujkovic, Aleksandar, Schmitt, Michael, Schnitzler, Paul, Müller-Tidow, Carsten, Dietrich, Sascha, Dreger, Peter, and Luft, Thomas
- Subjects
STEM cell transplantation ,COVID-19 vaccines ,ANTIBODY titer ,DISEASE exacerbation - Abstract
The COVID-19 pandemic threatens patients with a compromised immune and endothelial system, including patients who underwent allogeneic stem cell transplantation (alloSCT). Thus, there is an unmet need for optimizing vaccination management in this high-risk cohort. Here, we monitored antibodies against SARS-CoV-2 spike protein (anti-S1) in 167 vaccinated alloSCT patients. Humoral immune responses were detectable in 81% of patients after two vaccinations with either mRNA-, vector-based, or heterologous regimens. Age, B-cell counts, time interval from vaccination, and the type of vaccine determined antibody titres in patients without systemic immunosuppression (sIS). Similar to a healthy control cohort, mRNA vaccine-based regimens induced higher titres than vector-based vaccines. Patients on two or more immunosuppressants rarely developed immunity. In contrast, 62% and 45% of patients without or on only one immunosuppressant, respectively, showed a strong humoral vaccination response (titre > 100). Exacerbation of cGVHD upon vaccination was observed in 6% of all patients and in 22% of patients receiving immunosuppression for cGVHD. cGVHD exacerbation and low antibody titres were both associated with higher angiopoietin-2 (ANG2) serum levels. In conclusion, mRNA-based vaccines elicit strong humoral responses in alloSCT patients in the absence of double sIS. Biomarkers such as ANG2 might help with weighing cGVHD risk versus beneficial responses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Was macht ein Wissensingenieur?
- Author
-
Luft, Thomas and Wartzack, Sandro
- Abstract
Copyright of Wissens Management is the property of Nicole Lehnert - wissensmanagement and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
36. Verschiedene Rollen im Wissensmanagement - eine bibliografische Studie.
- Author
-
Luft, Thomas and Wartzack, Sandro
- Abstract
Copyright of Wissens Management is the property of Nicole Lehnert - wissensmanagement and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2014
37. Myelodysplastische Syndrome (MDS).
- Author
-
Luft, Thomas and Dreger, Peter
- Abstract
Copyright of Onkopipeline is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2009
- Full Text
- View/download PDF
38. Image Enhancement by Unsharp Masking the Depth Buffer.
- Author
-
Luft, Thomas, Colditz, Carsten, and Deussen, Oliver
- Subjects
MEDICINE ,PHOTOGRAPHS ,IMAGE processing ,IMAGING systems ,COMPUTER graphics - Abstract
We present a simple and efficient method to enhance the perceptual quality of images that contain depth information. Similar to an unsharp mask, the difference between the original depth buffer content and a low-pass filtered copy is utilized to determine information about spatially important areas in a scene. Based on this information we locally enhance the contrast, color, and other parameters of the image. Our technique aims at improving the perception of complex scenes by introducing additional depth cues. The idea is motivated by artwork and findings in the field of neurology, and can be applied to images of any kind, ranging from complex landscape data and technical artifacts, to volume rendering, photograph, and video with depth information. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
39. Real-Time Watercolor for Animation.
- Author
-
Luft, Thomas and Deussen, Oliver
- Abstract
We present algorithms that allow for real-time rendering of 3D-scenes with a watercolor painting appearance. Our approach provides an appropriate simplification of the visual complexity, imitates characteristic natural effects of watercolor, and provides two essential painting techniques: the wet-on-wet and the wet-on-dry painting. We concentrate on efficient algorithms based on image space processing rather than on an exact simulation. This allows for the real-time rendering of 3D-scenes. During an animation a high frame-to-frame coherence can be achieved due to a stable segmentation scheme. Finally, we seamlessly integrate a smooth illumination into the watercolor renderings using information from the 3D-scene. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
40. Overexpression, purification and characterization of SimL, an amide synthetase involved in simocyclinone biosynthesis.
- Author
-
Luft, Thomas, Shu-Ming Li, Scheible, Holger, Kammerer, Bernd, and Heide, Lutz
- Subjects
AMIDES ,LIGASES ,BIOSYNTHESIS ,BIOCHEMICAL engineering ,BIOCHEMISTRY ,ORGANIC synthesis - Abstract
Simocyclinone D8 is a potent inhibitor of bacterial gyrase, produced by Streptomyces antibioticus Tü 6040. It contains an aminocoumarin moiety, similar to that of novobiocin, which is linked by an amide bond to a structurally complex acyl moiety, consisting of an aromatic angucycline polyketide nucleus, the deoxysugar olivose and a tetraene dicarboxylic acid. We have now investigated the enzyme SimL, responsible for the formation of the amide bond of simocyclinone. The gene was cloned, expressed in S. lividans T7, and the protein was purified to near homogeneity, and characterized. The 60 kDa protein catalyzed both the ATP-dependent activation of the acyl component as well as its transfer to the amino group of the aminocoumarin ring, with no requirement for a 4′-phosphopantetheinyl cofactor. Besides its natural substrate, simocyclinone C4, SimL also accepted a range of cinnamic and benzoic acid derivatives and several other, structurally very diverse acids. These findings make SimL a possible tool for the creation of new aminocoumarin antibiotics. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. Dissociation of putative graft- versus-haematopoiesis and graft- versus-myeloma effects in patients with rapidly progressive multiple myeloma.
- Author
-
Luft, Thomas, Moos, Marion, Goldschmidt, Hartmut, Ho, Anthony D., and Görner, Martin
- Subjects
CELL transplantation ,COMPLICATIONS from organ transplantation ,MULTIPLE myeloma - Abstract
This study evaluates the immunological effects in 21 patients with multiple myeloma (MM) following allogeneic stem cell transplantation with a non-myeloablative conditioning regimen. Patients were heavily pretreated, most of them having progressed despite one to three courses of high dose chemotherapy followed by autologous stem cell rescue. For patients conditioned with low dose total body irradiation and Fludarabine, development of full (100%) donor chimerism (FDC) within the first 3–4 months strongly depended on the number of T cells transplanted. This putative graft- versus-haematopoiesis effect, however, did not coincide with clinical response. Rather, 10 of 17 patients progressed although FDC in peripheral blood was achieved. In contrast, clinical graft- versus-host disease (GvHD) of grade III–IV was associated with disease remission. Four of six patients achieved complete remission (CR) and one patient achieved a partial remission (PR) in close temporal relation with their acute GvHD. Two of four patients in CR succumbed to the consequences of this side effect. One patient in PR progressed soon after successful treatment of the GvHD, one of two patients with a long-lasting CR developed chronic GvHD. Our observations suggest the existence of two distinct immune effects in MM following allogeneic transplantations with reduced conditioning regimen. First, the putative graft- versus-haematopoiesis effect that induced FDC was observed in all patients receiving unmanipulated grafts. Secondly, the graft- versus-myeloma effect that induced CR did not correlate with FDC but was associated with grade III–IV GvHD in our group of heavily pretreated patients. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
42. Novobiocin biosynthesis: inactivation of the putative regulatory gene novE and heterologous expression of genes involved in aminocoumarin ring formation.
- Author
-
Eustáquio, Alessandra S., Luft, Thomas, Zhao-Xin Wang, Gust, Bertolt, Chater, Keith F., Shu-Ming Li, and Heide, Lutz
- Subjects
BIOSYNTHESIS ,BIOCHEMICAL engineering ,BIOCHEMISTRY ,GENES ,HYDROXYLATION ,CHEMICAL reactions - Abstract
The left ends of the biosynthetic gene clusters of novobiocin (nov), clorobiocin (clo) and coumermycin A
1 (cou) from Streptomyces spheroides (syn. S. caeruleus) NCIMB 11891, S. roseochromogenes var. oscitans DS 12.976 and S. rishiriensis DSM 40489 were cloned and sequenced. Sequence comparison suggested that novE, cloE and couE, respectively, represent the borders of these three clusters. Inactivation of novE proved that novE does not have an essential catalytic role in novobiocin biosynthesis, but is likely to have a regulatory function. The gene products of novF and cloF show sequence similarity to prephenate dehydrogenase and may produce 4-hydroxyphenylpyruvate (4HPP) as a precursor of the substituted benzoate moiety of novobiocin and clorobiocin. Coumermycin A1 does not contain this benzoate moiety, and correspondingly the coumermycin cluster was found not to contain a functional novF homologue. The coumermycin biosynthetic gene cluster apparently evolved from an ancestral cluster similar to those of novobiocin and clorobiocin, and parts of the ancestral novF homologue have been deleted in this process. No homologue to novC was identified in the gene clusters of clorobiocin and coumermycin, questioning the postulated involvement of novC in aminocoumarin biosynthesis. Heterologous expression of novDEFGHIJK in Streptomyces lividans resulted in the formation of 2,4-dihydroxy-α-oxy-phenylacetic acid, suggesting that at least one of the proteins encoded by these genes may participate in a hydroxylation reaction. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
43. IFN‐α enhances CD40 ligand‐mediated activation of immature monocyte‐derived dendritic cells.
- Author
-
Luft, Thomas, Luetjens, Petra, Hochrein, Hubertus, Toy, Tracey, Masterman, Kelly‐Anne, Rizkalla, Mark, Maliszewski, Charlie, Shortman, Ken, Cebon, Jonathan, and Maraskovsky, Eugene
- Abstract
Type I IFN are immune modulatory cytokines that are secreted during early stages of infection. Type I IFN bridge the innate and the adaptive immune system in humans and mice. We compared the capacity of type I and II IFN to induce the functional maturation of monocyte‐derived dendritic cells (MoDC). Extending our earlier observation that type I IFN promote DC maturation, we report that these cytokines also enhance DC differentiation by augmenting CD40 ligand (CD40L)‐induced cytokine secretion by MoDC. Type I IFN alone were poor inducers of MoDC maturation as compared with other stimuli. They up‐regulated the expression of HLA‐DR, CD80, CD86, partially CCR7 but not CD83, partially reduced antigen‐uptake function, increased the levels of IL‐12p35 mRNA, and prolonged surface expression of peptide–MHC class I complexes for presentation to cytotoxic T lymphocytes, but did not induce migration towards CCL21 chemokine. However, type I IFN were potent co‐factors for CD40L‐mediated function. Here, they enhanced CD40L‐mediated IL‐6, IL‐10 and IL‐12p70 secretion. Furthermore, when combined with IL‐1β and/or IL‐4, IFN‐α2a type I IFN increased CD40L‐mediated IL‐12p70 production by 2‐ to 3‐fold, and biased the IL‐12 p40/p70 ratio towards the IFN‐γ inducing p70 heterodimer, this correlating with higher levels of IFN‐γ secretion by allogeneic T cell subsets and NK cells. Our results suggest that the rapid expression of CD40L, IFN and IL‐1β at sites of infection and inflammation can act in concert on immature DC, thereby linking innate and adaptive immune responses. In this way, type I IFN play a dual role as DC maturation factors and enhancers of CD40L‐mediated DC activation. [ABSTRACT FROM PUBLISHER]
- Published
- 2002
- Full Text
- View/download PDF
44. Knowledge Based Engineering: Konstruktionsrelevantes Wissen erfassen & nutzbar machen.
- Author
-
Luft, Thomas, Roth, Daniel, and Wartzack, Sandro
- Abstract
Copyright of Wissens Management is the property of Nicole Lehnert - wissensmanagement and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
45. Welches Wissensmanagement-System passt zum Unternehmen?
- Author
-
Luft, Thomas, Frey, Dennis, and Wartzack, Sandro
- Published
- 2014
46. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
- Author
-
Radujkovic, Aleksandar, Hundemer, Michael, Eisenbach, Christoph, Luft, Thomas, Penzel, Roland, Goldschmidt, Hartmut, Ho, Anthony D., and Bellos, Frauke
- Subjects
VISCERAL leishmaniasis ,LEISHMANIASIS treatment ,MELPHALAN ,STEM cell transplantation ,INSECT bites & stings ,SAND flies ,PROGNOSIS - Abstract
The article presents the case of a 58-year-old patient with relapsed multiple myelomia and was diagnosed with visceral leishmaniasis. Topics include the possible causes of leishmaniasis including transfusion of blood products from healthy carriers, sandfly bite and reactivation of a sublinical/latent infection, and the link between the differential diagnosis of VL and patients with fever of unknown origin, obscure hepatosplenogmegaly and pancytopenia.
- Published
- 2014
- Full Text
- View/download PDF
47. Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation.
- Author
-
Pettengell, Ruth, Luft, Thomas, Wynter, Erika, Coutinho, Lucia, Young, Rosemary, Fitzsimmons, Lesley, Scarffe, J. Howard, and Testa, Nydia G.
- Published
- 1995
- Full Text
- View/download PDF
48. Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation.
- Author
-
Pettengell, Ruth, Luft, Thomas, Wynter, Erika, Coutinho, Lucia, Young, Rosemary, Fitzsimmons, Lesley, Scarffe, J. Howard, and Testa, Nydia G.
- Published
- 1995
- Full Text
- View/download PDF
49. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.
- Author
-
Radujkovic, Aleksandar, Boch, Tobias, Nolte, Florian, Nowak, Daniel, Kunz, Claudia, Gieffers, Alexandra, Müller-Tidow, Carsten, Dreger, Peter, Hofmann, Wolf-Karsten, and Luft, Thomas
- Subjects
BLOOD serum analysis ,ANEMIA ,APOPTOSIS ,BIOMARKERS ,CALCIUM-binding proteins ,CONFIDENCE intervals ,CYTOKINES ,ERYTHROPOIESIS ,INFLAMMATION ,INTERLEUKINS ,MYELODYSPLASTIC syndromes ,MYELOFIBROSIS ,RECOMBINANT proteins ,RISK assessment ,STATISTICS ,SURVIVAL ,DATA analysis ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,CHEMICAL inhibitors ,DISEASE risk factors - Abstract
Simple Summary: Asunercept showed promising clinical efficacy in anemic, transfusion-dependent patients with low and intermediate risk myelodysplastic syndrome. In this retrospective post hoc analysis, serum levels of biomarkers were measured in study patients focusing on cytokines associated with erythropoiesis, inflammation, apoptosis, bone marrow fibrosis, and inflammasome activity. Baseline serum biomarkers were correlated with treatment response in order to propose a hypothetical responder serum profile. Response to asunercept was associated with improved overall survival. Higher baseline values of interleukin-18 (IL-18), S100 calcium-binding protein A9 (S100A9) and soluble p53 were predictive of non-response to asunercept. Non-responding patients showed a distinct, pro-inflammatory serum cytokine profile which was persistent throughout the first half of the treatment phase and appeared unaffected by asunercept. Our post hoc analysis suggests that serum cytokine profiling based on IL-18, S100A9 and soluble p53 may represent an approach to identify and select low-risk myelodysplastic syndrome patients most likely to benefit from asunercept treatment. Asunercept (APG101) is a well-tolerated CD95-ligand inhibitor that showed promising efficacy in a prospective, single-arm phase I study in anemic, transfusion-dependent patients with low and intermediate risk myelodysplastic syndrome (MDS). In this retrospective post hoc analysis, serum levels of biomarkers were measured in study patients focusing on cytokines associated with erythropoiesis, inflammation, apoptosis, bone marrow fibrosis, and inflammasome activity. Baseline serum biomarkers were correlated with treatment response, in order to propose a hypothetical responder serum profile. After an updated median follow-up of 54 months (range 7–65), response to asunercept was associated with improved overall survival (at 3-years: 67% [95%CI 36–97] versus 13% [95%CI 0–36] in responders versus non-responders, respectively). Higher baseline values of interleukin-18 (IL-18), S100 calcium-binding protein A9 (S100A9) and soluble p53 were predictive of non-response to asunercept (area under the receiver operating characteristic curve 0.79–0.82). Furthermore, non-responding patients showed a distinct, pro-inflammatory serum cytokine profile which was persistent throughout the first half of the treatment phase and appeared unaffected by asunercept. Although prospective validation is required, our post hoc analysis suggests that serum cytokine profiling based on IL-18, S100A9 and soluble p53 may represent an approach to identify and select low-risk MDS patients most likely to benefit from asunercept treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
50. Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation.
- Author
-
Radujkovic, Aleksandar, Kordelas, Lambros, Bogdanov, Rashit, Müller-Tidow, Carsten, Beelen, Dietrich W., Dreger, Peter, and Luft, Thomas
- Subjects
HEMATOPOIETIC stem cell transplantation ,INTERLEUKINS ,POSTOPERATIVE care - Abstract
Simple Summary: We have previously shown that high pre-conditioning levels of Interleukin-18 were associated with worse survival after allogeneic stem cell transplantation due to increased non-relapse mortality. While no correlations with acute graft-versus-host disease were observed, interleukin-18-related excess mortality was mainly driven by fatal infectious complications. In multiple studies, delayed hematopoietic recovery and poor graft function following allogeneic stem cell transplantation has been demonstrated as a powerful predictor of non-relapse mortality. The present study links high interleukin-18 to delayed platelet recovery in allografted patients. Given the functions of interleukin-18 in regulating the quiescence of hematopoietic stem/progenitor cells, our findings may be explained by Interferon gamma-independent inhibitory effects of interleukin-18 on stem cell proliferation and hematopoietic reconstitution in allografted patients. Importantly, considering recent successful interleukin-18-neutralizing approaches in autoimmune disorders, our results provide a rationale to explore modulation of interleukin-18 for improving hematopoietic recovery and outcomes in allogeneic stem cell transplantation recipients. Interleukin-18 (IL-18) is an immunoregulatory cytokine and a context-dependent regulator of hematopoietic stem/progenitor cell (HSPC) quiescence in murine models. In a previous study, high pre-conditioning levels of IL-18 were associated with increased non-relapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). To investigate the clinical impact of IL-18 status on hematopoietic function, the associations of pre-conditioning and day 0–3 cytokine levels with platelet and neutrophil recovery were analyzed in a training cohort of 714 allografted patients. In adjusted logistic regression analyses, both increasing pre-conditioning and day 0–3 IL-18 levels had a significantly higher adjusted odds ratio (aOR) of delayed platelet and neutrophil recovery on day +28 post-transplant (aOR per two-fold increase: 1.6–2.0). The adverse impact of high pre-conditioning IL-18 on day +28 platelet recovery was verified in an independent cohort of 673 allografted patients (aOR per two-fold increase: 1.8 and 1.7 for total and free IL-18, respectively). In both cohorts, a platelet count ≤20/nL on day +28 was associated with a significantly increased hazard of NRM (hazard ratio 2.13 and 2.94, respectively). Our findings support the hypothesis that elevated peritransplant IL-18 levels affect post-transplant HSPC function and may provide a rationale to explore modulation of IL-18 for improving alloSCT outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.